BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Retrophin, LLC Names Stephen Aselage as Chief Executive Officer


9/10/2012 9:19:32 AM

Industry veteran brings more than 30 years of pharmaceutical expertise

Strong track record in rare diseases and global markets

Company moves headquarters to San Diego

NEW YORK--(BUSINESS WIRE)--Retrophin, LLC, a privately held biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced that it has named Stephen Aselage as its new Chief Executive Officer, effective October 16. Aselage was named to the Board on September 6. The company also announced that it is moving its headquarters from New York City to San Diego, CA, where it already has an office.

Aselage brings more than 30 years of pharmaceutical/biotechnology expertise to Retrophin. He joins the company from BioMarin Pharmaceutical Inc., where he was Executive Vice President and Chief Business Officer. During his seven years with BioMarin, he built the commercial and medical affairs functions that launched three commercial products and developed commercial business in more than 45 countries.

“We welcome Steve’s global pharmaceutical experience across multiple disciplines, expertise in rare diseases, and leadership acumen to Retrophin,” said Martin Shkreli, President and Founder of Retrophin. “Steve shares my vision and passion for finding treatments to help people with rare, life-threatening diseases, which make him an ideal candidate for CEO. His experience in enabling patients access to critical medications around the globe is particularly useful, as we want to ensure that every patient who might benefit from our treatments has the opportunity to do so.”

“I’m excited to be leading the Retrophin team at a time when the company has so many opportunities for growth and promising treatments for rare diseases in the pipeline,” said Aselage. “I look forward to drawing from my experience in rare diseases as I work to contribute to Retrophin’s bright future.”

Aselage also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. He worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat. Earlier in his career, he held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) and Bristol Laboratories. Aselage received his B.S. in Biology from the University of Notre Dame.

About Retrophin, LLC

Retrophin, LLC is a privately held biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for focal segmental glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. The company’s lead compound, RE-021, formerly known as DARA, is scheduled to begin enrollment in a Phase II clinical trial for FSGS in the near future. Retrophin's Series A financing was led by MSMB Capital and several current and former senior executives at global pharmaceutical and healthcare companies.

Contacts

Retrophin, LLC
Tom Fernandez, President (MSMB Capital), 646-837-5861
tom@msmbcapital.com
or
6 Degrees
Tony Plohoros, Principal, 908-591-2839
tplohoros@6degreespr.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES